



(Incorporated in the Cayman Islands with Limited Liability)

Stock Code: 0575

2 December 2020

ANNOUNCEMENT




Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

OPERATIONS UPDATE ON FORTACIN™



The directors (the “**Directors**” or the “**Board**”) of Regent Pacific Group Limited (the “**Company**” and collectively with its subsidiaries, the “**Group**”) wish to inform the shareholders of the Company and potential investors of the following update in respect of its operations in relation Senstend™/ Fortacin™.



Further to the last operations update issued by the Company on 17 November 2020, the Directors are pleased to inform shareholders that Wanbang Pharmaceutical Marketing and Distribution Co., Ltd. (“**Wanbang Pharmaceutical**”), the Company’s commercial strategic partner for China, has received approval from the National Medical Products Administration (“**NMPA**”) to submit the investigational new drug application for human clinical trial of a Licensed Product at NMPA, which is an important milestone in achieving approval to market Senstend™ in China. Plethora has accordingly issued to Wanbang Pharmaceutical an invoice for US\$800,000 (or approximately HK\$6.24 million), which is payable within 30 business days. NMPA will now formally review for Clinical Trial Approval (“**CTA**”) and the Company has been advised by Wanbang Pharmaceutical that the CTA will be obtained from the Center of Drug Evaluation within 60 working days (approximately 3 months) from the date of submission, i.e. by end of



Q1 2021. Upon the successful approval from NMPA to commence the clinical trial a payment of US\$3.20 million (or approximately HK\$24.96 million) will be due.

The Group will continue to work closely and diligently with its current and prospective commercial partners and will keep shareholders and potential investors informed of any new developments as and when they occur.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

Note: Unless otherwise specified herein, the amounts dominated into US\$ have been translated, for the purpose of illustration only, into HK\$ using the exchange rate of US\$1.00 = HK\$7.80.

On Behalf of the Board of
Regent Pacific Group Limited

Jamie Gibson
Executive Director

Directors of the Company:

James Mellon (*Chairman*)*

Jamie Gibson (*Chief Executive Officer*)

David Comba[#]

Julie Oates[#]

Mark Searle[#]

Jayne Sutcliffe*

* *Non-Executive Directors*

[#] *Independent Non-Executive Directors*

Hong Kong, 2 December 2020